Stock 4591 RIBOMIC INC.
Add to a list
To use this feature you must be a member
Log inSign up

Financials Ribomic Inc.

Equities

4591

JP3974850004

Biotechnology & Medical Research

Market Closed - Japan Exchange
Other stock markets
 02:00:00 2024-05-02 am EDT 		5-day change 1st Jan Change
86 JPY +3.61% Intraday chart for Ribomic Inc. +4.88% -20.37%
Mar. 07 Ribomic Inc. announced that it has received ¥4.192212 million in funding from SMBC Nikko Securities Inc. CI
Feb. 20 Ribomic Inc. announced that it expects to receive ¥4.192212 million in funding from SMBC Nikko Securities Inc. CI

Valuation

Fiscal Period: March 2018 2019 2020 2021 2022 2023
Capitalization 1 9,867 9,569 5,513 10,159 5,997 6,710
Enterprise Value (EV) 1 7,688 8,157 3,513 4,321 1,296 2,385
P/E ratio -12.6 x -11.4 x -5.86 x -7.88 x -3.5 x -3.54 x
Yield - - - - - -
Capitalization / Revenue 154 x 1,367 x 45.6 x 112 x 75 x 103 x
EV / Revenue 120 x 1,165 x 29 x 47.5 x 16.2 x 36.7 x
EV / EBITDA -8.79 x -9.04 x -3.92 x -3.56 x -0.75 x -1.34 x
EV / FCF -14.8 x -13.3 x -5.14 x -5.69 x -1.38 x -1.97 x
FCF Yield -6.76% -7.52% -19.5% -17.6% -72.4% -50.8%
Price to Book 4.46 x 6.46 x 2.43 x 1.69 x 1.28 x 1.53 x
Nbr of stocks (in thousands) 14,136 14,390 17,556 27,909 28,559 35,693
Reference price 2 698.0 665.0 314.0 364.0 210.0 188.0
Announcement Date 6/29/18 6/28/19 7/31/20 6/30/21 6/29/22 6/28/23
1JPY in Million2JPY
Estimates

Income Statement Evolution (Annual data)

Fiscal Period: March 2018 2019 2020 2021 2022 2023
Net sales 1 64 7 121 91 80 65
EBITDA 1 -875 -902 -897 -1,214 -1,734 -1,787
EBIT 1 -900 -929 -914 -1,240 -1,749 -1,787
Operating Margin -1,406.25% -13,271.43% -755.37% -1,362.64% -2,186.25% -2,749.23%
Earnings before Tax (EBT) 1 -752 -835 -854 -1,186 -1,683 -1,652
Net income 1 -753 -836 -855 -1,187 -1,684 -1,653
Net margin -1,176.56% -11,942.86% -706.61% -1,304.4% -2,105% -2,543.08%
EPS 2 -55.60 -58.17 -53.62 -46.16 -59.92 -53.14
Free Cash Flow 1 -519.5 -613.6 -683.2 -759 -939.1 -1,211
FCF margin -811.72% -8,766.07% -564.67% -834.07% -1,173.91% -1,862.88%
FCF Conversion (EBITDA) - - - - - -
FCF Conversion (Net income) - - - - - -
Dividend per Share - - - - - -
Announcement Date 6/29/18 6/28/19 7/31/20 6/30/21 6/29/22 6/28/23
1JPY in Million2JPY
Estimates

Income Statement Evolution (Quarterly data)

Fiscal Period: March 2020 S1 2021 S1 2022 S1 2022 Q3 2023 Q1 2023 S1 2023 Q3 2024 Q1 2024 S1 2024 Q3
Net sales 3 4 5 2 2 3 - - - -
EBITDA - - - - - - - - - -
EBIT 1 -400 -563 -778 -348 -632 -927 -585 -338 -581 -248
Operating Margin -13,333.33% -14,075% -15,560% -17,400% -31,600% -30,900% - - - -
Earnings before Tax (EBT) 1 -398 -587 -767 -346 -612 -878 -597 -334 -554 -247
Net income 1 -399 -588 -767 -347 -613 -878 -598 -334 -554 -248
Net margin -13,300% -14,700% -15,340% -17,350% -30,650% -29,266.67% - - - -
EPS 2 -25.91 -25.01 -27.51 -12.35 -21.47 -30.77 -19.10 -9.390 -15.55 -6.950
Dividend per Share - - - - - - - - - -
Announcement Date 11/12/19 11/12/20 11/9/21 2/14/22 8/9/22 11/11/22 2/10/23 8/10/23 11/13/23 2/13/24
1JPY in Million2JPY
Estimates

Balance Sheet Analysis

Fiscal Period: March 2018 2019 2020 2021 2022 2023
Net Debt 1 - - - - - -
Net Cash position 1 2,179 1,412 2,000 5,838 4,701 4,325
Leverage (Debt/EBITDA) - - - - - -
Free Cash Flow 1 -520 -614 -683 -759 -939 -1,211
ROE (net income / shareholders' equity) -32.3% -45.1% -46.7% -29% -31.5% -36.4%
ROA (Net income/ Total Assets) -23.3% -23.7% -23.6% -18.5% -19.7% -23.4%
Assets 1 3,227 3,524 3,621 6,424 8,529 7,057
Book Value Per Share 2 157.0 103.0 129.0 215.0 164.0 123.0
Cash Flow per Share 2 111.0 98.20 95.00 120.0 102.0 79.20
Capex 1 14 16 46 1 10 23
Capex / Sales 21.88% 228.57% 38.02% 1.1% 12.5% 35.38%
Announcement Date 6/29/18 6/28/19 7/31/20 6/30/21 6/29/22 6/28/23
1JPY in Million2JPY
Estimates

EPS & Dividend

Year-on-year evolution of the PER

Change in Enterprise Value/EBITDA

Quarterly earnings - Rate of surprise

Company calendar

Sector Bio Therapeutic Drugs

1st Jan change Capi.
RIBOMIC INC. Stock Ribomic Inc.
-20.37% 20.25M
REGENERON PHARMACEUTICALS, INC. Stock Regeneron Pharmaceuticals, Inc.
+8.96% 105B
VERTEX PHARMACEUTICALS INCORPORATED Stock Vertex Pharmaceuticals Incorporated
-1.43% 104B
ARGENX SE Stock argenx SE
+4.40% 22.94B
BIONTECH SE Stock BioNTech SE
-12.15% 22.34B
GENMAB A/S Stock Genmab A/S
-4.36% 19.25B
WUXI APPTEC CO., LTD. Stock WuXi AppTec Co., Ltd.
-39.98% 17.08B
BEIGENE, LTD. Stock BeiGene, Ltd.
-10.04% 16.96B
NEUROCRINE BIOSCIENCES, INC. Stock Neurocrine Biosciences, Inc.
+6.79% 14.16B
SAREPTA THERAPEUTICS, INC. Stock Sarepta Therapeutics, Inc.
+38.61% 12.63B
Bio Therapeutic Drugs
  1. Stock Market
  2. Equities
  3. 4591 Stock
  4. Financials Ribomic Inc.